Impact of Blood Viscosity on Oxygen Delivery in humans with Sickle Cell Anemia

Children'S Hospital Of Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Abstract

Sickle cell disease (SCD) is an inherited disorder of hemoglobin that causes normally flexible red blood cells to become very rigid and obstruct blood flow leading to ischemia, organ damage and ultimately, death. The pathophysiology of SCD is due in part to the increase in blood viscosity caused by hemoglobin S (HbS). Chronic transfusions markedly reduce sickle episodes and protect against recurring stroke and acute chest syndrome, presumably by reducing HbS and improving viscosity. However, the optimal reduction in HbS needed to prevent complications is not known. Our preliminary data suggests that changes in HbS and hematocrit that improve arterial flow may be detrimental in low shear flow areas like the cerebral cortex and heart. The effect of changes in blood viscosity on high and low shear flow and oxygen delivery has not been measured in humans with SCD. Goals: This project will determine the relation between prefrontal cerebral cortex oxygen delivery, cerebral arterial flow and blood viscosity and %HbS. Furthermore, we want to validate easily determined, noninvasive measures of regional oxygen delivery and perfusion that could be clinical surrogates for consequences of sickling for management and for testing new therapies. AIMS: We will 1) determine the relation of oxygen delivery and blood flow in regions of high and low shear to blood viscosity in chronically transfused patients over a wide range of HbS% and during the change in %HbS that occurs during simple or exchange transfusion, 2) determine if total nighttime hypoxia and loss of heart rate variability, a measure of autonomic dysregulation, are surrogates for the effects of disordered viscosity, and 3) if pre-frontal cerebral oxygen content, nighttime hypoxia and autonomic function improve in parallel with improvement in exercise tolerance and pain-free days after dietary supplementation with glutamine. Aim 3 will be done in collaboration with the randomized glutamine trial proposed in Project 2B (PI:Niihara).